From September 30, 2023 to December 29, 2023, the company has repurchased 9,287,000 shares, representing 2.99% for $208.42 million. With this, the company has completed the repurchase of 26,230,000 shares, representing 8.25% for $550 million under the buyback announced on March 20, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.37 USD | -1.79% | -2.42% | -10.92% |
05-10 | Exelixis Files Patent Complaint Against Cipla's Cancer Treatment | DJ |
05-01 | RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.92% | 6.22B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on March 20, 2023.